HDAC-IN-73 (compound p-503), an effective HDAC inhibitor, exhibits IC 50 values of 0.17 and 0.49 µM for HDAC1 and HDAC6 respectively. This compound promotes apoptosis and arrests the cell cycle at the G2/M phase. Additionally, HDAC-IN-73 demonstrates anti-tumor activity.

HDAC1:0.17 μM, HDAC6:0.49 μM

HDAC-IN-73 (compound p-503) at concentrations of 0-2 µM over 24 hours enhances the protein expression of Ac-α-tubulin and Ac-H3 in HCT116 cells [1]. At concentrations of 0.1-0.4 µM, HDAC-IN-73 can induce apoptosis and cause cell cycle arrest at the G2/M phase [1].

HDAC-IN-73 administered intraperitoneally at a dosage of 5 mg/kg every two days for 26 days effectively inhibits tumor growth in the HCT116 xenograft model [1]. Animal Model: 6-week-old female nude mice (BALB/c-nu) [1]. Dosage: 5 mg/kg Administration: I.p.; every 2 days for 26 days. Result: Achieved a significant tumor growth inhibition (TGI) of 74.6%.